Your browser doesn't support javascript.
loading
Improvement of metabolic syndrome and its components in patients who underwent transsphenoidal resection for pituitary adenoma.
Cortés-Contreras, A P; Salazar-Pigeon, A; González-Almazán, J A; Flores-Rabasa, R; Navarro-Olvera, J L; Méndez-García, L A; Carrillo-Ruiz, J D.
Affiliation
  • Cortés-Contreras AP; Functional & Stereotactic Neurosurgery Unit, Mexico General Hospital, CDMX, Mexico.
  • Salazar-Pigeon A; Immunometabolism Laboratory. Research Direction, Mexico General Hospital, CDMX, Mexico.
  • González-Almazán JA; Faculty of Medicine, National Autonomous University of Mexico, CDMX, Mexico.
  • Flores-Rabasa R; Scholarship Holder of the General Direction of Quality and Education in Health, Health Secretary, CDMX, Mexico.
  • Navarro-Olvera JL; Immunometabolism Laboratory. Research Direction, Mexico General Hospital, CDMX, Mexico.
  • Méndez-García LA; Faculty of Medicine, National Autonomous University of Mexico, CDMX, Mexico.
  • Carrillo-Ruiz JD; Functional & Stereotactic Neurosurgery Unit, Mexico General Hospital, CDMX, Mexico.
Acta Neurochir (Wien) ; 166(1): 86, 2024 Feb 16.
Article in En | MEDLINE | ID: mdl-38363400
ABSTRACT

BACKGROUND:

Pituitary adenomas (PA) are neoplasms of pituitary adenohypophyseal cell lineage, which are the third most common cause of brain tumors among adults. Due to hormone secretion, PAs are closely related to metabolic syndrome (MetS). However, the relationship between these two entities has been scarcely studied to date.

PURPOSE:

This paper aims to evaluate changes in the metabolic status of patients with PA before and after surgical treatment and to look for differences in metabolic outcomes among patients according to the adenoma type and the surgery success rate.

METHODS:

We assessed patients with PA who went through transsphenoidal surgery for its treatment, documenting metabolic parameters before and after surgery, analyzed whole sample changes, and then stratified them according to adenoma type (nonfunctioning, somatotroph, lactotroph, and corticotroph), and surgery success (total resection, near-total resection, partial resection, subtotal resection).

RESULTS:

A total of 214 patients were enrolled for this study. The prevalence of MetS with AACE criteria went from 51.52% before surgery to 28.99% after surgery (P < 0.001). Hyperglycemia (HG) was the most beneficial component; it went from 56% pre-surgery to 40.51% post-surgery (P = 0.03). The total resection group had the best improvement, with a significant decrease of prevalence in MetS from 83 to 16% (P < 0.001), and every component, except hypoalphalipoproteinemia (HA) obesity went from 96 to 67% (P < 0.001), arterial hypertension (AH) 59 to 24% (P < 0.001), HG 74 to 23% (P < 0.001), and hypertriglyceridemia (HTG) from 81 to 54% (P < 0.001). According to MetS prevalence, there was no difference in the improvement according to PA type.

CONCLUSION:

Surgical treatment in patients with PA is associated with MetS improvement.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pituitary Neoplasms / Adenoma / Metabolic Syndrome Type of study: Risk_factors_studies Limits: Adult / Humans Language: En Journal: Acta Neurochir (Wien) Year: 2024 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pituitary Neoplasms / Adenoma / Metabolic Syndrome Type of study: Risk_factors_studies Limits: Adult / Humans Language: En Journal: Acta Neurochir (Wien) Year: 2024 Document type: Article Affiliation country: